BioCentury
ARTICLE | Company News

BTG, J&J sales and marketing update

December 14, 2015 8:00 AM UTC

The U.K.’s NICE issued a second final appraisal determination (FAD) recommending against the use of Zytiga abiraterone from Johnson & Johnson to treat metastatic castration-resistant prostate cancer (CRPC) in patients whose first treatment has failed and for whom chemotherapy is not yet clinically indicated. The committee concluded that Zytiga compared with placebo extended the time to progression but was uncertain how much it extended life. NICE concluded that the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained for Zytiga compared to best supportive care was L35,500-L59,600 ($53,523-$89,859), above the range considered an acceptable use of NHS resources.

In August 2014, NICE issued the first FAD. J&J submitted an amended patient access scheme (PAS) and the appraisal was referred back to the appraisal committee (see BioCentury, Sept. 1, 2014). ...